Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas;La gammagrafía de receptores de somatostatina en el diagnóstico y estadificación de los tumores neuroendocrinos del aparato digestivo y páncreas

Revista Espanola de Medicina Nuclear

Volumn 19, Issue 3, 2000, Pages 225-241

  Banzo, Javier ^a   Abos M D ^a   Prats, E ^a   Garcia F ^a   Razola, P ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; INDIUM 111; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; YTTRIUM 90; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; NEUROPEPTIDE; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SDZ 215 811; SDZ 215-811; TUMOR MARKER; TUMOR PROTEIN;

ANGIOGRAPHY; CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; DOWN REGULATION; GASTRINOMA; GLUCAGONOMA; HUMAN; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSTATINOMA; TUMOR DIAGNOSIS; UPREGULATION; VIPOMA; ALGORITHM; ANIMAL; BINDING COMPETITION; CANCER STAGING; CHEMISTRY; EVALUATION; GASTROINTESTINAL TUMOR; INTERVENTIONAL RADIOLOGY; METASTASIS; METHODOLOGY; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; SCINTISCANNING; SECRETION; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; ANIMALS; BINDING, COMPETITIVE; CLINICAL TRIALS, PHASE I; GASTROINTESTINAL NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; NEUROPEPTIDES; OCTREOTIDE; PANCREATIC NEOPLASMS; PENTETIC ACID; RADIOLOGY, INTERVENTIONAL; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0006462555     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of inmunoreactive pituitary growth hormone. Science 1973;179: 77-9.
2. Hall R, Snow M, Scanlon M, Mora B, Gómez-Pan A. Pituitary effects of somatostatin. Metabolism 1978(Supl 1):1257-62.
3. Reichlin S. Somatostatin (first of two parts). N Engl J Med 1983;309:1495-501.
4. Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983;309:1556-63.
5. Bauer W, Briner U, Doepfner W, Haller R, Huguerin R, Marbach P, et al. Pless J SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolongued action. Life Sci 1982;31:1133-40.
6. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-82.
7. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide.
8. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L, et al. Localization of endocrine related tumours with radioiodinated analogue of somatostatin. Lancet 1989;I:242-5.
9. 1)-octreotide in somatostatin receptor-positive tumor-bearing animal. Life Sci 1991;49:1593-601.
10. Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33:652-8.
11. Reubi JC, Kvols L, Krenning E, Lamberts SWJ. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990;39 (Supl 2):78-81
12. Burbach JP, Meijer OC. The estructure of neuropeptide receptors. Eur J Pharmacol 1992;227:1-18.
13. Yamada Y, Post SR, Wang K, Tagr HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 1992; 89:251-5.
14. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, et al. Cloning functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993;195:844-52.
15. Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hsstr1-5) are funcionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994;198:605-12.
16. Fischman AJ, Babich JW. Radiolabeled peptides: a new class of imaging agents. En: Freeman LM, ed. Nuclear Medicine Annual 1997. Filadelfia: Lippincott-Raven; 1997. p. 103-31.
17. Blok D, Feitsma RIJ, Vermeij P, Pauwels EJK. Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med 1999;26:1511-20.
18. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995;36:1825-35.
19. Jhon M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherübl H, et al. Positive somatostatin receptor scintigraphy correlated with the presence of somatostatin receptor subtype 2. Gut 1996;38:33-9.
20. Schwarz AL, Fridovich SE, Lodisch HF. Kinetics of internalization and recycling of the asialoglycoprotein receptor in hepatoma cell line. J Biok Chem 1982;257:4230-7.
21. 1-octreotide. J Nucl Med 1996;37:2002-6.
22. Lamberts SWJ, Hofland LJ, van Koetzveld PM, Reubi JC, Bruining HA, Bakker WH, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab 1990;71:566-74.
23. Krening EP, Kwekkeboom DJ, Oei HY, de Jong RJB, Dop FJ, Reubi JC, et al. Somatostatin receptors in gastroenteropancreatic tumors: on overview of European results. Ann NY Acad Sci 1994;733:416-24.
24. Kvols LK, Reubi JC. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med 1992;65:505-12.
25. Nilsson O, Kölvy L, Wängberg B, Wigander A, Billig H, William-Olsson L, et al. Comparative studies on the expression of somatostatin receptor subtipes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998;77:632-7.
26. Dörr U, Räth U, Sautter-Bihl ML, Guzman G, Bach D, Adrian AJ, et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993;20:431-3.
27. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. En: Freeman LM, ed. Nuclear Medicine Annual 1995. Filadelfia: Lippincott-Raven;1995. p. 1-50.
28. Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (OctreoScan) Semin Nucl Med 1995;25:251-61.
29. 111In-pentetreótida en el estudio de tumores que expresan receptores para la somatostatina. Rev Esp Med Nucl 1999; 18:325-30.
30. 3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
31. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. ICRP publication 53, Oxford: Pergamon 1988.
32. Varas MJ. Diagnóstico de los síndromes de hipersecreción hormonal. En: Varas MJ ed. Endocrinología gastroentero-pancreática. Byk Elmu y Pharmacia&Upjohn; 1997. p. 145-71.
33. Buchanan KD, Johnston CF, O'Hare MMT, Ardill JES, Shaw C, Collins JSA, et al. Neuroendocrine tumors. A european view. Am J Med 1986;81 (Supl 6B):14-22.
34. Kaplan LM. Tumores endocrinos del tubo digestivo y del páncreas. En: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hause SL, Longo DL, eds. Harrison: Principios de Medicina Interna, 14.° Edición, Madrid; McGraw-Hill; 1998. Vol, 1. p. 665-75.
35. Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (Today). Gastroenterology 1997;112:583-90.
36. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858-68.
37. Duh QY, Hybarger CP, Geist R, Gamsu G, Goodman PC, Gooding GAW, et al. Carcinoids associated with multiple endocrine neoplasia syndromes. Am J Surg 1987;154:142-8.
38. Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991;12:181-7.
39. Rosch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV, Kenjiro V, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992;326:1721-6.
40. 111In-DTPA-octreotide receptor scintigraphy in GEP tumours: a comparison of trials. Update 1994;1:32-4.
41. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patients management. J Nucl Med 1995;36:542-9.
42. Faraggi M. Clinical interest of octreoscan scintigraphy in gastroentero-pancreatic (GEP) tumours. Update 1995;2:16-8.
43. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Inter Med 1996; 125:26-34.
44. Cadiot G, Lebtahi R, Sarda L, Bonnaud G, Marmuse JP, Vissuzaine C, et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996;111:845-54.
45. Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993;16:34-8.
46. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994;21:561-81.
47. Nour R, Quinn RJ, Morris DL, Butler SP. Avid thallium-201 uptake in hepatic carcinoid metastases. Eur J Nucl Med 1993;20:804-6.
48. Kvols LK. Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors. Gastroenterology 1993;105:1909-11.
49. De Kerviler E, Cadiot G, Lebhati R, Faraggi M, Le Guludec D, Mignon M, et al. Sudy Group. Somatostatin receptor scintigraphy in forty-eight patients with the Zollonger-Ellison syndrome. Eur J Nucl Med 1994;21:1191-7.
50. Yeung HWD, Imbriaco M, Zhang JJ, Macapinlac H, Godsmith SJ, Larson SM. Visualization of miocardial metastasis of carcinoid tumor by indium-111-pentetreotide. J Nucl Med 1996;37:1528-30.
51. Gibril F, Doppman JL, Reinolds JC, Chen C, Surliff VE, Serrano J, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somastatatin receptor scintigraphy and magnetic resonance imaging in their detection, frequency, location and effect of their detection on management. J Clin Oncol 1998;16:1040-53.
52. Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999;40:1602-8.
53. Schillaci O, Scopinaro F, Angeletti S, Tavoloro R, Danieli R, Annibale B, et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 1996;37:1452-6.
54. Corleto VD, Scopinaro F, Angeletti S, Materia A, Basso N, Polettini E, et al. Somatostatin receptor localization of pancreatic endocrine tumors. World J Surg 1996;20:241-4.
55. Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, et al. Specificty of somatostatin scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999;40:539-53.
56. Rusznievski Ph, Amouyal P, Amouyal G, Grangé JD, Mignon M, Bouché O, et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zolliger-Ellison syndrome. Surgery 1995;117:629-35.
57. 111In-octreotide scan in a case of a neuroendocrine tumor of unknown origin. Clin Nucl Med 1999;24:955-8.
58. Fishbeyn VA, Norton JA, Benya RV, Pisegna JR, Venzon DJ, Metz DC, et al. Assesment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Inter Med 1993;119:199-206.
59. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-8.
60. Vinik AI, Tsai ST, Moattari AR, Cheung P, Eckhauser FE, Cho K. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med 1986;81(Supl 6B):23-39.
61. Orloff SL, Debas HT. Advances in the management of patients with Zolliger-Ellison syndrome. Surg Clin Nor Am 1995;75:511-24.
62. Selverstone B, Solomon AK, Sweet WH. Location of brain tumors by means of radiactive phosphorus. JAMA 1949;73:115-9.
63. Selverstone B, Sweet WH, Robinson CV. The clinical use of radioactive phosphorus in the surgery of brain tumors. Ann Surg 1949;130:643-51.
64. Hoffman EJ, Tornai MP, Janecek M, Patt BE, Iwanczyk JS. Intraoperative probes and imaging probes. Eur J Nucl Med 1999;26:913-35.
65. 125I-TYR(3) -octreotide and a hand-held gamma-detecting probe. Surgery 1993;114:745-52.
66. Woltering EA, Barrie R, O'Dorisio TM, O'Dorisio MS, Nance R, Cook DM. Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection. Surgery 1994;116:1139-47.
67. Ahlman H, Wängberg B, Tisell LE, Nilsson O, Fjälling M, Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg 1994;81:1144-9.
68. 1- octreotide. Br J Cancer 1996;73:770-5.
69. Adams S, Baum RP, Hertel A, Wenisch HJC, Staib-Sebler E, Herrman G, et al. Intraoperative gamma probe detecting of neuroendocrine tumors. J Nucl Med 1998;39:1155-60.
70. 99mTechnetium somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med 1999;26:869-76.
71. 111In-labeled radiopharmaceuticals. J Nucl Med 1999;40:2094-101.
72. 1)-octreotide: a case history. Ann NJ Acad Sci 1994;733:496-506.
73. 1-octreotide in midgut carcinoide syndrome. J Nucl Med 1996;37:1519-21.
74. 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 1998;4:94-102.
75. 111In-DTPA-octreotide. Update 1998;4:16-9.
76. 3)octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368-71.
77. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792-5.
78. 90Yttrium-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-8.
79. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999;40:762-7.
80. 90Y-DOTATOC. Eur J Nucl Med 1999;26: 877-86.
81. 1)-octreotide. Eur J Nucl Med 1998;25:884.
82. 90Yttrium-octreotide renal uptake. J Nucl Med 1997;38:1929-33.
83. 90Ytrium-DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439-47.